FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer

Journal of Clinical Oncology

Volumn 24, Issue 23, 2006, Pages 3747-3755

  Thussbas, Christoph ^a   Nahrig, Jorg ^a   Streit, Sylvia ^a   Bange, Johannes ^a   Kriner, Monika ^a   Kates, Ronald ^a   Ulm, Kurt ^a   Kiechle, Marion ^a   Hoefler, Heinz ^a   Ullrich, Axel ^a   Harbeck, Nadia ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ARGININE; GLYCINE; TUMOR MARKER;

ALLELE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENETIC MARKER; GENETICS; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; MULTIVARIATE ANALYSIS; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARGININE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC MARKERS; GENOTYPE; GLYCINE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION, MISSENSE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; TUMOR MARKERS, BIOLOGICAL;

EID: 33747363496     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.8587     Document Type: Article

References (35)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336, 1991
2. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87:159-170, 1996
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
4. Mulligan LM, Kwok JB, Healey CS, et al: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458-460, 1993
5. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73, 1997
6. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
7. Burke D, Wilkes D, Blundell TL, et al: Fibroblast growth factor receptors: Lessons from the genes. Trends Biochem Sci 23:59-62, 1998
8. Rousseau F, Bonaventure J, Legeai-Mallet L, et al: Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371:252-254, 1994
9. Meyers GA, Orlow SJ, Munro IR, et al: Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 11:462-464, 1995
10. Arman E, Haffner-Krausz R, Gorivodsky M, et al: Fgfr2 is required for limb outgrowth and lung-branching morphogenesis. Proc Natl Acad Sci U S A 96:11895-11899, 1999
11. Reardon W, Winter RM, Rutland P, et al: Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 8:98-103, 1994
12. Jabs EW, Li X, Scott AF, et al: Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet 8:275-279, 1994
13. Cappellen D, De Oliveira C, Ricol D, et al: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23:18-20, 1999
14. Jang JH, Shin KH, Park JG: Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61:3541-3543, 2001
15. Xiao S, Nalabolu SR, Aster JC, et al: FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 18:84-87, 1998
16. Chesi M, Nardini E, Brents LA, et al: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-264, 1997
17. Feng S, Wang F, Matsubara A, et al: Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 57:5369-5378, 1997
18. Marics I, Padilla F, Guillemot JF, et al: FGFR4 signaling is a necessary step in limb muscle differentiation. Development 129:4559-4569, 2002
19. Penault-Llorca F, Bertucci F, Adelaide J, et al: Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 61:170-176, 1995
20. Jacquemier J, Adelaide J, Parc P, et al: Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer 59:373-378, 1994
21. Leung HY, Gullick WJ, Lemoine NR: Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer 59:667-675, 1994
22. Takahashi A, Sasaki H, Kim SJ, et al: Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem Biophys Res Commun 257:855-859, 1999
23. Bange J, Prechtl D, Cheburkin Y, et al: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62:840-847, 2002
24. Streit S, Bange J, Fichtner A, et al: Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111:213-217, 2004
25. Spinola M, Leoni V, Pignatiello C, et al: Functional FGFR4 Gly388Arg Polymorphism Predicts Prognosis in Lung Adenocarcinoma Patients. J Clin Oncol 23:7307-7311, 2005
26. EBCTCG: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
27. Harbeck N, Alt U, Berger U, et al: Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7:2757-2764, 2001
28. Walch A, Specht K, Bink K, et al: Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia- adenocarcinoma sequence of Barrett's esophagus. Lab Invest 81:791-801, 2001
29. Jezequel P, Campion L, Joalland MP, et al: G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 90:189-193, 2004
30. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791-808, 1998
31. Morimoto Y, Ozaki T, Ouchida M, et al: Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98: 2245-2250, 2003
32. Harbeck N, Kates RE, Schmitt M: Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 20:1000-1007, 2002
33. Wang J, Stockton DW, Ittmann M: The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 10:6169-6178, 2004
34. Harbeck N, Kates RE, Schmitt M, et al: Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5:348-352, 2004
35. Chandrasekar N, Mohanam S, Gujrati M, et al: Downregulation of uPA inhibits migration and PI3k/ Akt signaling in glioblastoma cells. Oncogene 22: 392-400, 2003